What was recalled
This page synthesizes the cellular agriculture regulatory framework around commercial pet food. Cellular agriculture refers to the production of animal products (meat, dairy, leather, others) through cell culture rather than traditional animal agriculture. The relevant subcategories for pet food are: (i) cultured meat (also called cell-based meat, lab-grown meat) — muscle cells harvested from a living animal, expanded in culture, differentiated into mature muscle and fat tissue, and harvested as meat product; (ii) precision fermentation (covered separately on our precision-fermented animal protein page) — microbial production of specific animal proteins through fermentation; (iii) plant molecular farming — production of animal proteins in plant hosts (less commercially developed); (iv) animal-free dairy through precision fermentation. The regulatory framework intersects across these subcategories with different jurisdictional and pathway considerations.
The November 2018 FDA-USDA joint regulatory framework agreement established the US oversight structure for cultured meat. Under the framework, FDA-CVM has jurisdiction over cell collection (including biopsy from donor animals, cell line establishment, cell bank maintenance), cell growth and proliferation in bioreactors, differentiation processes (muscle tissue formation, fat tissue formation, scaffolding integration if applicable), and pre-harvest quality control. USDA-FSIS has jurisdiction over harvest of the cultured tissue from bioreactor through processing, packaging, labeling, and inspection of the final product for cultured meat from livestock species (cattle, pork, poultry, sheep, goat, deer, bison, others). Cultured seafood remains entirely under FDA jurisdiction. The framework was the result of multi-agency negotiation through 2017-2018 and provides a clear regulatory pathway for human food applications.
The commercial approval trajectory has accelerated through 2020-2024. Singapore became the first national jurisdiction to approve cultured meat for commercial sale with Eat Just’s JUST chicken (December 2020), through the Singapore Food Agency novel food regulatory framework. The Singapore approval established cultured meat commercial viability and provided a template for subsequent national approvals. US first commercial cultured meat approvals followed in 2022-2023: Upside Foods received FDA "no questions" letter for cultured chicken cell line safety (November 2022), Upside Foods received USDA grant of inspection for the Emeryville California processing facility (June 2023), GOOD Meat (Eat Just US subsidiary) received FDA "no questions" letter (March 2023) and USDA grant of inspection (June 2023). Commercial launch in US restaurants began mid-2023 through high-end restaurant partnerships in San Francisco and Washington DC. Israel approved cultured beef from Aleph Farms (January 2024), the third national jurisdiction. Multiple additional jurisdictions have cultured meat regulatory frameworks in development.
Why it was recalled
The structural concerns have three layers. Layer one — pet food regulatory pathway lags human food framework: the FDA-USDA joint framework applies to human food cultured meat, with cultured pet food applications operating in a separate (and less developed) regulatory pathway. AAFCO has not yet defined cultured meat for commercial pet food use. Companies developing cultured pet food (Bond Pet Foods, BioCraft Pet Foods, Because Animals, others) face regulatory uncertainty about which pathway will apply — AAFCO Ingredient Definitions Committee (IDC) approval (typical 5-7 year timeline), FDA-CVM no-questions-letter (informal federal recognition), state-level cross-reference from FDA human food no-questions-letter, or FDA food additive petition. The framework is evolving with the human food framework providing some structural template but pet-food-specific framework still in development.
Layer two — consumer disclosure framework around "cultured" labeling is incomplete: the FDA-USDA joint framework includes labeling considerations for cultured meat in human food, with ongoing rulemaking about appropriate descriptive terminology (cell-cultured, cultivated, lab-grown, cell-based, others). The pet food equivalent labeling framework is essentially undefined. Consumer disclosure around the cellular agriculture nature of pet food ingredients varies across brands and could become inconsistent without explicit AAFCO model regulation. The framework intersects with broader truth-in-labeling considerations and with consumer-preference dynamics around recombinant-DNA-derived ingredients.
Layer three — long-term companion animal feeding evidence is essentially absent: like other novel-ingredient categories (BSF, cricket, mealworm, precision-fermented animal protein), cultured meat for pet food has not been subject to long-term cohort feeding studies in companion animals. The cultured meat product is biologically equivalent to conventional animal muscle and fat tissue at the cellular and molecular tier (favorable from a nutritional safety standpoint), but the long-term feeding evidence base for commercial pet food applications is limited. Short-term safety studies and palatability studies have been published for some cultured meat preparations, but multi-year cohort feeding evidence is not available. The framework places cultured meat at the leading edge of pet food ingredient innovation where commercial product and long-term evidence are evolving together.
Health risks for your pet
Cultured meat produced through standard cellular agriculture processing meets food safety requirements equivalent to other USDA-FSIS or FDA-regulated food ingredients in jurisdictions where it is approved. The product is biologically equivalent to conventional animal muscle and fat tissue at the cellular and molecular tier, providing nutritional adequacy expected to match conventional animal sourcing. Theoretical health-impact concerns include: (i) cell line genetic stability — cellular agriculture relies on cell lines maintained over many doubling generations, with theoretical concern about genetic drift; safety review at FDA "no questions" letter addresses this but the framework is not zero; (ii) bioreactor process residuals — cell culture media components (growth factors, serum or serum-free formulations, antibiotics if used) may leave trace residuals in the cultured tissue; downstream processing addresses this but residual framework is not zero; (iii) scaffolding material residuals — cultured meat preparations using edible scaffolding (alginate, cellulose, plant fiber) may contain residual scaffold material with varying digestibility and gut-impact profile; (iv) long-term companion animal feeding evidence gap — multi-year cohort evidence is not available, leaving the long-term safety profile partly extrapolated from human food approval review rather than companion-animal-specific evidence.
The more substantive concern is regulatory pathway uncertainty for pet food applications: companies developing cultured pet food operate in a regulatory framework that is still developing. Commercial product entering pet food markets may rely on AAFCO IDC tentative-definition status, FDA-CVM no-questions-letters, state-level cross-reference from FDA human food approvals, or pending AAFCO definitions. Consumer disclosure around regulatory pathway is essentially absent. Pet owners selecting pet food with cultured meat ingredients are operating in an innovation-tier category with developing regulatory framework and limited consumer-disclosure transparency relative to established ingredients.
What to do if you bought affected product
Pet owners can navigate cellular agriculture pet food meaningfully through several practical approaches: (1) treat cultured meat pet food as an innovation-tier ingredient — the category has commercial human food precedent in multiple jurisdictions (Singapore 2020, US 2022-2023, Israel 2024) but developing pet food regulatory framework with limited long-term companion-animal feeding evidence; (2) verify regulatory pathway disclosure — request from brand customer service which regulatory pathway applies (AAFCO IDC tentative or official definition, FDA-CVM no-questions-letter, FDA food additive petition, state-level cross-reference from FDA human food approval); brands with well-managed regulatory affairs typically have this documentation; (3) recognize that cultured meat is biologically equivalent to conventional animal tissue at the cellular and molecular tier — nutritional adequacy is expected to match conventional sources; allergenicity is expected to be similar to the source species (cultured chicken may produce chicken-allergy-like response in sensitive pets); (4) treat the cultured-meat nature as a consumer-preference dimension — some pet owners prefer cultured alternatives (animal-welfare and sustainability considerations), others prefer conventional animal sources; the choice is value-based rather than safety-based for properly-regulated ingredients; (5) introduce cultured-meat pet food gradually over a 1-2 week transition period — novel protein introduction recommendations apply equivalently to cultured alternatives; (6) discuss cultured-meat pet food options with your veterinarian for pets with chronic conditions or specific dietary needs; (7) watch the AAFCO Ingredient Definitions Committee, FDA-CVM regulatory updates, USDA-FSIS framework evolution, and Pet Food Industry trade press for regulatory framework development — cellular agriculture pet food regulation is actively evolving in parallel with human food framework; (8) reference our cultured meat pet food controversy and precision-fermented animal protein pages for related emerging-category context.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently include cultured meat in the database per our published methodology, since commercial pet food products using these ingredients are limited and AAFCO ingredient definition framework is still developing. Future rubric extension under consideration: as cultured meat reaches AAFCO definition status or FDA-CVM no-questions-letter status with broader commercial pet food adoption, rubric integration would address nutritional adequacy (biological equivalence to conventional animal tissue), sustainability favorability (substantially lower land, water, and greenhouse gas footprint than conventional livestock agriculture), and long-term feeding evidence (developing). The broader cellular agriculture and emerging-category framework is covered across our cultured meat pet food controversy, precision-fermented animal protein, black soldier fly larvae, and tranche-14 alternative protein controversy pages. For now, our recommendation: treat cellular agriculture pet food as innovation-tier ingredients with full regulatory clearance through some pathway but limited long-term companion-animal feeding evidence, and approach with gradual introduction and veterinary consultation for special populations.